Intranasal drug delivery devices are medical devices used to deliver drugs through the nasal route for both local and systemic effects. The devices provide non-invasive and needle-free routes of drug administration and offer advantages such as rapid drug absorption, avoiding hepatic first-pass metabolism, and better patient compliance. Intranasal delivery of drugs is widely used for treatment of allergies, migraines, pain, insulin delivery, and emergency conditions.
Global intranasal drug delivery devices market is estimated to be valued at USD 1.70 Bn in 2024 and is expected to reach USD 3.27 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031.
Key Takeaways
Key Players: Key players operating in the intranasal drug delivery devices market are OptiNose US Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Cadila Pharmaceuticals, Mylan N.V., Emergent BioSolutions Inc., and Novartis AG.
Key Opportunities: Rising prevalence of chronic conditions like diabetes, migraine headaches, Parkinson's disease and Alzheimer's disease is fueling the Intranasal Drug Delivery Devices Market Trends for non-invasive drug delivery methods. This presents lucrative opportunities for devices that can effectively deliver drugs intranasally to achieve both local and systemic effects.
Global Expansion: Major players are focusing on geographical expansion plans in emerging markets to leverage high growth opportunities. Mergers, acquisitions, partnerships, and collaborations are helping companies strengthen their market presence and global footprint.
Market Drivers:
- Increasing prevalence of chronic diseases like diabetes, asthma and migraine headaches is a major market driver as it is generating demand for alternative drug administration routes. According to the World Health Organization, chronic disease burden is expected to reach 57% of total global deaths by 2020.
- Growing preference for self-administration and needle-free drug delivery is boosting the adoption of intranasal devices. The non-invasive nature makes them suitable for self-administration of drugs at home settings.
Market Restraints:
- Nasal physiology and clearance mechanisms pose challenges to developing effective intranasal drug formulations and may slow market growth. Factors like mucociliary clearance, drainage via nasolacrimal duct and enzymatic drug metabolism in nasal epithelia can hinder drug absorption.
- High development costs and regulatory strictness associated with device approval may act as a bottleneck negatively impacting the market in the short term. Stringent rules on safety and performance often delay market entry
Segment Analysis
This market consists of nasal spray, nasal drops and gels, nasal powders and nasal packaging segment. The nasal spray segment held the largest market share owing to its convenience of use and effectiveness. It dominated more than 50% of the overall market. Growth is attributed to rising preference among patients and caregivers for nasal sprays due to its ease of self administration.
The global market is analyzed by regions including North America, Europe, Asia Pacific and Rest of the world. North America region captured the largest revenue share owing to increased healthcare expenditures and growing awareness regarding intranasal administration of drugs. Asia Pacific is considered as the fastest growing region attributed to increasing focus of generic manufacturers towards new drug development coupled with rising prevalence of chronic respiratory diseases.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment